Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürma...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma...
Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
A new era of early cancer detection with blood test may change cancer screening ...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable he...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Lenvatinib remains standard of care for first-line therapy in advanced hepatocel...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and...
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Lasofoxifene shows promise for women with ESR1-mutated mBC
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...
Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Scientists discover mechanism of action and an actionable inflammatory axis for ...
Prof Charles Swanton - The Francis Crick Institute, London, UK
Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC ( Prof Charles Swanton - The Francis Crick Institute, London, UK )
10 Sep 2022
Bladder cancer: Current state and future directions in treatment
Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case ...
Bladder cancer: Current state and future directions in treatment ( Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA )
15 Aug 2022
Optimum treatment algorithm in management of advanced prostate cancer
Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case ...
Optimum treatment algorithm in management of advanced prostate cancer ( Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA )
15 Aug 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
Prostate roundup what have we learned from EAU and ASCO 2022?
Prof Eleni Efstathiou and Prof Nicolas Mottet
Prostate roundup what have we learned from EAU and ASCO 2022? ( Prof Eleni Efstathiou and Prof Nicolas Mottet )
11 Jul 2022